The following Life Sciences practice note provides comprehensive and up to date legal information covering:
A complex array of requirements and guidelines developed at EU, EU Member State and UK levels govern the following aspects of medicinal products:
clinical testing (ie clinical trials)
placing on the market (ie marketing authorisation (MA) and regulatory procedure for approval of medicinal products)
protection of the pre-clinical and clinical data developed for the purposes of obtaining an MA (ie regulatory data protection)
manufacture and importation
labelling and package leaflet
advertising and promotion
wholesale distribution and brokering
pricing and reimbursement
medicines for rare diseases (ie orphan medicinal products (OMPs))
advanced therapy medicinal products (ATMPs)
unlicensed medicines and off-label use of authorised medicines
There has been a rapid expansion of law on these subjects at the EU level, with increased harmonisation in many areas. EU Member State requirements and guidelines still, however, remain essential parts of the EU regulatory picture. There are considerable differences among EU Member States in their approach to implementation and enforcement.
The key laws and regulations governing medicinal products are:
Directive 2001/83/EC, the Pharmaceutical Code which establishes the regulatory framework for the sale, production, labelling, classification, distribution and advertising of medicinal products for human use
Regulation (EC) 726/2004, the EMA Regulation establishes the EU medicines regulator, the European Medicines Agency (EMA) and lays down
Free trials are only available to individuals based in the UK
Complete all the fields above to proceed to the next step.
**Trials are provided to all LexisPSL and LexisLibrary content, excluding Practice Compliance, Practice Management and Risk and Compliance, subscription packages are tailored to your specific needs. To discuss trialling these LexisPSL services please email customer service via our online form. Free trials are only available to individuals based in the UK. We may terminate this trial at any time or decide not to give a trial, for any reason. Trial includes one question to LexisAsk during the length of the trial.
To view the latest version of this document and thousands of others like it, sign-in to LexisPSL or register for a free trial.
Existing user? Sign-in
Take a free trial
Take a free trial
Defects liability period and rectification of defectsIt is common in construction projects for defects to manifest or appear in the works. Most construction contracts require the contractor to return to site to rectify (also known as ‘make good’) defects which arise or are discovered during a
The Financial Assistance Scheme—what are the available benefits?THIS PRACTICE NOTE APPLIES TO SCHEMES ENTERING THE FINANCIAL ASSISTANCE SCHEME FROM 1 JANUARY 2012.Where a scheme, its employer(s) and individual members have satisfied the criteria for eligibility into the Financial Assistance Scheme
Contract interpretation—express terms in contractsExpress and implied contractual terms distinguishedContractual terms may be either express or implied:•express terms—are terms which are actually recorded in a written contract or openly expressed in an oral contract at the time the contract is made
Negligence—when is the duty of care breached?Having established that a duty of care exists (see Practice Note: Negligence—when does a duty of care arise?), it is then necessary to consider whether or not there has been a breach of that duty. This will depend on a number of factors outlined below and
0330 161 1234